Bio

Clinical Focus

  • Neurology

Academic Appointments

Professional Education

  • Residency: Stanford University Neurology Residency (2020) CA
  • Internship: California Pacific Medical Center Dept of Medicine (2017) CA
  • Medical Education: Boston University School of Medicine (2016) MA
  • Residency, Stanford University Neurology Residency (2020)
  • Internship, California Pacific Medical Center Internal Medicine Residency (2017)
  • Medical Education, Boston University School of Medicine (2016)

Contact

  • Stanford Neuroscience Health Center 213 Quarry Rd 2nd Fl MC 5957 Palo Alto, CA 94304
    • Tel: (650) 723-6469
    Fax: (650) 725-0390

Publications

All Publications

  • Administration of Dexamethasone for Bacterial Meningitis: An Unreliable Quality Measure NEUROHOSPITALIST Dujari, S., Gummidipundi, S., He, Z., Gold, C. A. 2020

    View details for DOI 10.1177/1941874420969556

    View details for Web of Science ID 000600210200001

  • ACEP Guidelines on Acute Nontraumatic Headache Diagnosis and Management in the Emergency Department, Commentary on Behalf of the Refractory, Inpatient, Emergency Care Section of the American Headache Society. Headache Peretz, A., Dujari, S., Cowan, R., Minen, M. 2020

    Abstract

    The American College of Emergency Physicians (ACEP) published guidelines in July 2019 on the diagnosis and management of acute nontraumatic headaches in the emergency department, focusing predominantly on the diagnosis of subarachnoid hemorrhage and the role of imaging and lumbar puncture in diagnosis. The ACEP Clinical Policies document is intended to aide Emergency Physicians in their approach to patients presenting with acute headache and to improve the accuracy of diagnosis, while promoting safe patient care practices. The Clinical Policies document also highlights the need for future research into best practices to distinguish primary from secondary headaches and the efficacy and safety of current treatment options for acute headaches. The following commentary on these guidelines is intended to support and expand on these guidelines from the Headache specialists' perspective, written on behalf of the Refractory, Inpatient, Emergency Care section of the American Headache Society (AHS). The commentary have been reviewed and approved by Board of Directors of the AHS.

    View details for DOI 10.1111/head.13744

    View details for PubMedID 31944291

  • Utilization, yield, and accuracy of the FilmArray Meningitis/Encephalitis panel with diagnostic stewardship and testing algorithm. Journal of clinical microbiology Broadhurst, M. J., Dujari, S., Budvytiene, I., Pinsky, B. A., Gold, C. A., Banaei, N. 2020

    Abstract

    Background: The impact of diagnostic stewardship and testing algorithms on utilization and performance of the FilmArray® Meningitis/Encephalitis (ME) Panel has received limited investigation.Methods: We performed a retrospective single-center cohort study assessing all individuals with suspected ME between February 2017 and April 2019 for whom the ME Panel was ordered. Testing was restricted to patients with cerebrospinal fluid (CSF) pleocytosis. Positive ME Panel results were confirmed before reporting through correlation with direct stain (Gram and Calcofluor white) and CSF Cryptococcal antigen or by repeat ME Panel testing. Outcomes included ME Panel test utilization rate, negative predictive value of non-pleocytic CSF samples, test yield and false-positivity rate, and time to appropriate de-escalation of acyclovir.Results: Restricting testing to pleocytic CSF samples reduced ME Panel utilization by 42.7% (263 vs 459 tests performed) and increased test yield by 61.8% (18.6% vs 11.5% positivity rate; P < 0.01) with application of criteria. The negative predictive value of normal CSF WBC for ME Panel targets was 100% (195/195) for non-viral targets and 98.0% (192/196) overall. All pathogens detected in non-pleocytic CSF samples were herpesviruses. Application of a selective testing algorithm based on repeat testing of non-viral targets avoided 75% (3/4) of false-positive results without generating false-negative results. Introduction of the ME panel reduced the duration of acyclovir treatment from an average of 66 hours (SD, 43) to 46 hours (SD, 36) (P = 0.03).Conclusions: Implementation of the ME Panel with restriction criteria and a selective testing algorithm for non-viral targets optimizes its utilization, yield and accuracy.

    View details for DOI 10.1128/JCM.00311-20

    View details for PubMedID 32493787

  • Infected Implantable Pulse Generator NEUROHOSPITALIST Dujari, S., Gold, C. A. 2019; 9 (3): 172?73

    View details for DOI 10.1177/1941874418809869

    View details for Web of Science ID 000471642900011

    View details for PubMedID 31244976

    View details for PubMedCentralID PMC6582390

  • Making Well Neurologists: A Multifaceted Program for Neurology Trainee and Faculty Wellbeing Miller-Kuhlmann, R., Murray, N., Dujari, S., Karamian, A., Hamidi, M., Su, E., Bozinov, N., McGranahan, T. LIPPINCOTT WILLIAMS & WILKINS. 2019

    View details for Web of Science ID 000475965902083

  • Design and Implementation of a Novel Acute Stroke Code for the Extended Window of Endovascular Treatment Legault, C., Dujari, S., Shen, S. H., Wagner, A. M., Albers, G., Bernier, E., Callagy, P., Vora, N. LIPPINCOTT WILLIAMS & WILKINS. 2018

    View details for Web of Science ID 000453090803006

Footer Links:

Stanford Medicine Resources: